These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27000667)

  • 1. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.
    Foglieni C; Pagano K; Lessi M; Bugatti A; Moroni E; Pinessi D; Resovi A; Ribatti D; Bertini S; Ragona L; Bellina F; Rusnati M; Colombo G; Taraboletti G
    Sci Rep; 2016 Mar; 6():23432. PubMed ID: 27000667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.
    Pinessi D; Foglieni C; Bugatti A; Moroni E; Resovi A; Ribatti D; Rusnati M; Giavazzi R; Colombo G; Taraboletti G
    Thromb Res; 2016 Apr; 140 Suppl 1():S182. PubMed ID: 27161705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.
    Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L
    PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2).
    Rusnati M; Borsotti P; Moroni E; Foglieni C; Chiodelli P; Carminati L; Pinessi D; Annis DS; Paiardi G; Bugatti A; Gori A; Longhi R; Belotti D; Mosher DF; Colombo G; Taraboletti G
    Angiogenesis; 2019 Feb; 22(1):133-144. PubMed ID: 30168023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
    J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Basis of the Antiangiogenic Action of Rosmarinic Acid, a Natural Compound Targeting Fibroblast Growth Factor-2/FGFR Interactions.
    Pagano K; Carminati L; Tomaselli S; Molinari H; Taraboletti G; Ragona L
    Chembiochem; 2021 Jan; 22(1):160-169. PubMed ID: 32975328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach.
    Pagano K; Listro R; Linciano P; Rossi D; Longhi E; Taraboletti G; Molinari H; Collina S; Ragona L
    Bioorg Chem; 2023 Jul; 136():106529. PubMed ID: 37084585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.
    Colombo G; Margosio B; Ragona L; Neves M; Bonifacio S; Annis DS; Stravalaci M; Tomaselli S; Giavazzi R; Rusnati M; Presta M; Zetta L; Mosher DF; Ribatti D; Gobbi M; Taraboletti G
    J Biol Chem; 2010 Mar; 285(12):8733-42. PubMed ID: 20056600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
    Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
    Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors.
    Taraboletti G; Rusnati M; Ragona L; Colombo G
    Oncotarget; 2010 Nov; 1(7):662-673. PubMed ID: 21317461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A computational model of fibroblast growth factor-2 binding to endothelial cells under fluid flow.
    Patel NS; Reisig KV; Clyne AM
    Ann Biomed Eng; 2013 Jan; 41(1):154-71. PubMed ID: 22825797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling.
    Gupta AA; Chou RH; Li H; Yang LW; Yu C
    Biochim Biophys Acta; 2013 Dec; 1834(12):2606-19. PubMed ID: 24063890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44.
    Hibino S; Shibuya M; Hoffman MP; Engbring JA; Hossain R; Mochizuki M; Kudoh S; Nomizu M; Kleinman HK
    Cancer Res; 2005 Nov; 65(22):10494-501. PubMed ID: 16288042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
    Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
    Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptides derived from specific interaction sites of the fibroblast growth factor 2-FGF receptor complexes induce receptor activation and signaling.
    Manfè V; Kochoyan A; Bock E; Berezin V
    J Neurochem; 2010 Jul; 114(1):74-86. PubMed ID: 20374425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic function of antithrombin is dependent on its conformational variation: implication for other serpins.
    Azhar A; Singh P; Rashid Q; Naseem A; Khan MS; Jairajpuri MA
    Protein Pept Lett; 2013 Apr; 20(4):403-11. PubMed ID: 23016581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
    de Aguiar RB; Parise CB; Souza CR; Braggion C; Quintilio W; Moro AM; Navarro Marques FL; Buchpiguel CA; Chammas R; de Moraes JZ
    Cancer Lett; 2016 Feb; 371(2):151-60. PubMed ID: 26655277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.